A Randomized, Double Blinded, Placebo-Controlled Clinical Trial Evaluating the Efficacy and Safety of anti-SARS-CoV-2 Convalescent Plasma in Hospitalized Patients (CONTAIN COVID-19)
DOI10.5281/zenodo.5652143Zenodo5652143MaRDI QIDQ6675490FDOQ6675490
Dataset published at Zenodo repository.
Hyunah Yoon M.D., Gia F Cobb Ma, Mila B. Ortigoza M.D., Ph.D., For the Contain Study Group, Keith Goldfeld, Liise-Anne Pirofski M.D.
Publication date: 13 December 2021
This dataset contains de-identified patient data of 941 patients from 21 centers across the United States who wereenrolled in the CONTAIN COVID-19 randomized controlled trialthat ran from 4/17/2020-3/15/2021. The information in this dataset was used to conduct the analysis reported in the CONTAIN COVID-19 manuscript published in JAMA Internal Medicine (doi: 10.1001/jamainternmed.2021.6850)and includes demographic information, baseline history, baseline medications, baseline laboratory values, clinical status based on the WHO 11-point scale at 14 and 28 days after randomization, antibody titers, randomization arms.
This page was built for dataset: A Randomized, Double Blinded, Placebo-Controlled Clinical Trial Evaluating the Efficacy and Safety of anti-SARS-CoV-2 Convalescent Plasma in Hospitalized Patients (CONTAIN COVID-19)
